SCHEMBL10102657

SCHEMBL10102657

OCCCc1cc2cc(C(F)(F)F)ccc2nc1-c1ccoc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPBWR1 P48145 1/20 0.44
KDM4E B2RXH2 1/20 0.37
BACE1 P56817 1/20 0.35
CTSK P43235 1/20 0.34
KCNH2 Q12809 1/20 0.34
ERN1 O75460 1/20 0.34
MLYCD O95822 1/20 0.33
GPBAR1 Q8TDU6 1/20 0.33
DHODH Q02127 3/20 0.33
TRPV1 Q8NER1 2/20 0.32
PIK3R1 P27986 1/20 0.31
PIK3CA P42336 1/20 0.31
PDE3B Q13370 1/20 0.31
PDE3A Q14432 1/20 0.31
P2RY12 Q9H244 1/20 0.31
GRM5 P41594 1/20 0.30
ESRRB O95718 1/20 0.30
ESRRA P11474 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3383001 0.83 DHODH (0.45) NPBWR1KDM4ECTSKKCNH2DHODH
SCHEMBL13005263 0.82 DHFR (0.40) KDM4EBACE1CTSKKCNH2DHODH
SCHEMBL10107977 0.81 NPBWR1 (0.43) NPBWR1KDM4EBACE1CTSKKCNH2
SCHEMBL10102652 0.81 TRPA1 (0.43) KDM4EBACE1CTSKKCNH2DHODH
SCHEMBL10102644 0.80 GPBAR1 (0.42) KDM4EBACE1CTSKKCNH2GPBAR1
SCHEMBL13005264 0.79 KDM4E (0.39) KDM4EBACE1CTSKKCNH2DHODH
SCHEMBL10102653 0.79 CTSK (0.40) NPBWR1KDM4EBACE1CTSKKCNH2
SCHEMBL10107982 0.76 KDM4E (0.36) KDM4EBACE1CTSKKCNH2DHODH
SCHEMBL10102646 0.76 CTSK (0.47) CTSKKCNH2
SCHEMBL10102671 0.76 DHODH (0.46) NPBWR1KDM4EBACE1KCNH2DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207345-B2 Antitumor agents; use in combination with other drugs such as pentamidine MERCK PATENT GMBH (DE) 2012-06-26 US disclosed
US-8207345-B2 Antitumor agents; use in combination with other drugs such as pentamidine MERCK PATENT GMBH (DE) 2012-06-26 US disclosed
EP-1891011-B1 TETRAHYDROQUINOLINES USED IN THE FORM OF MODULATORS OF MITOTIC MOTOR-PROTEINS EG5 MERCK PATENT GMBH (DE) 2010-12-08 EP disclosed
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 MERCK PATENT GMBH (DE) 2008-08-21 US disclosed
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 MERCK PATENT GMBH (DE) 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 KIF5A, KIF5C, KIF5B NPBWR1 3668/4885KDM4E 2071/4885BACE1 4159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.